cell therapy - CarboHyde

How do you see the future of cell and gene therapy?

Jul 2, 2024Tamas Sohajdadrug developmentbiologics, cell therapy, CPHI, gene therapy

Our concise outlook is the following:

Transformational Potential: Cell and gene therapies are revolutionizing how we treat diseases, promising to cure certain conditions.
They remain at the forefront of healthcare innovation.

Fast-Growing Field: These therapies are the fastest-growing therapeutics areas, with over 50 new in vivo and ex vivo gene therapy launches planned in the next few years.

Challenges and Innovation: While promising, cell and gene therapies require substantial innovation to unlock their full potential for patients. Scaling digital and analytics in discovery and R&D is part of the solution.

Market Resilience: Despite the disruptions caused by the pandemic, stakeholders, including CGT innovators, healthcare providers, and CDMOs, are optimistic that positive developments lie ahead.

Viral-Vector Therapies: Viral-vector gene therapies are here to stay, but addressing challenges and strategizing for patient access is critical for their success.

Overall, the outlook is positive, but ongoing research, regulatory advancements, and manufacturing innovations will shape the future of cell and gene therapy. 🌟

Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies

Glycosylation, a near-universal feature of this class of drugs, is a critical quality attribute that significantly influences the physical properties, safety profile and biological activity of therapeutic proteins. Optimizing protein glycosylation offers an important avenue to developing more efficacious therapies.
In this review, Nathan Lewis’s team discusses specific examples of how variations in glycan structure and glycoengineering impact the stability, safety, and clinical efficacy of protein-based drugs that are already in the market and those still in preclinical development. We also highlight the impact of glycosylation on next-generation biologics such as T cell-based cancer therapy and gene therapy.